ZINC000002107582
ZINC000002107582 is a UVRAG binder. ZINC000002107582 induces Apoptosis, increases intracellular ROS levels, arrests the cell cycle at the S phase, and elevates the proportion of cells in the Sub G0 phase. ZINC000002107582 exhibits anticancer activity against breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 859138-65-1
- Formula: C31H31NO6
- Molecular Weight:513.58
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
ZINC000002107582 (0.195-50 μM; 24 h) potently inhibits MCF-7 cell viability with an IC50 of 5 μM, showing a concentration-dependent cytotoxic effect over 24 h[1].
ZINC000002107582 (5-10 μM; 24 h) induces dose-dependent apoptosis in MCF-7 cells, with 53.91% early apoptotic cells at IC50 (5 μM) and 80.67% total apoptotic cells at 2×IC50 (10 μM) after 24 h[1].
ZINC000002107582 (5-10 μM; 24 h) induces dose-dependent intracellular ROS accumulation in MCF-7 cells, with 71.51% ROS-positive cells at IC50 (5 μM) and 83.97% ROS-positive cells at 2×IC50 (10 μM) after 24 h[1].
ZINC000002107582 (5-10 μM; 24 h) induces S-phase cell cycle arrest and increases the Sub-G0 apoptotic population in MCF-7 cells, with more pronounced effects at 2×IC50 (10 μM) than at IC50 (5 μM) after 24 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human breast carcinoma MCF-7 cells
-
Concentration:0.195-50 μM
-
Incubation Time:24 h
-
Result:Caused a concentration-dependent reduction in cell viability.
Showed a slight reduction at 0.195-0.39 μM, a noticeable decrease at 0.781-3.125 μM, a pronounced reduction at 6.25-12.5 μM, and a significant decrease at 25-50 μM.
Reached a half-maximal inhibitory concentration (IC50) of 5 μM.
-
Cell Line:human breast carcinoma MCF-7 cells
-
Concentration:5 μM (IC50); 10 μM (2×IC50)
-
Incubation Time:24 h
-
Result:Resulted in 53.91% early apoptotic cells at IC50, while treatment at 2×IC50 resulted in 80.67% total apoptotic cells.
Showed a dose-dependent increase in apoptotic cell populations relative to untreated controls.
-
Cell Line:human breast carcinoma MCF-7 cells
-
Concentration:5 μM (IC50); 10 μM (2×IC50)
-
Incubation Time:24 h
-
Result:Reduced the G0/G1 population to 38.13%, increased the S-phase fraction to 25%, increased the Sub-G0 population to 6.82%, and decreased the G2/M phase to 25.69% at IC50.
Increased the S-phase fraction to 34%, increased the Sub-G0 population to 12.09%, decreased the G2/M phase to ~10%, and kept the G0/G1 fraction reduced relative to untreated controls at 2×IC50.
Chemical Information
-
CAS No. 859138-65-1
-
Molecular Weight 513.58
-
Formula C31H31NO6
-
SMILES
O=C(C1(C2=CC=CC=C2)CCN(C(CC3=C(C)C4=CC5=C(OC6=C5CCCC6)C(C)=C4OC3=O)=O)CC1)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz